Mediso has secured approval from the US Food and Drug Administration (FDA) for its InterView FUSION and InterView XP multimodality (PET/SPECT/MRI/CT) image processing and reporting software.
The Hungary-based medical imaging company has specifically adapted the InterView software for nuclear medicine and molecular imaging workflows.
The software, which is vendor-independent, is specifically developed to offer a comprehensive solution for image visualisation, post-processing, and reporting.
It has specialised tools and workflows to cover common nuclear medicine studies like bone, cardiac, central nervous system, thyroid, parathyroid, liver, kidney, lung, and digestive system.
The tool offers quick, standardised reporting for all nuclear medicine procedures, Mediso said.
Mediso CEO and founder Istvan Bagamery said: “Receiving the FDA nod for our image processing software marks the next step in marketing our clinical products in the USA.
“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application and they demonstrate our continuous commitment to the molecular imaging market.”
The nuclear medicine image processing software is said to improve SPECT image quality through iterative reconstruction and achieves absolute quantitation with its Tera-Tomo SPECT reconstruction engine for fast and accurate dosimetry.
Additionally, InterView includes several advanced modules like automatic segmentation, automatic lesion detection and image denoising to improve clinical and preclinical research work.
The Hungarian firm claimed that the nuclear medicine image processing software integrates seamlessly into any hospital information system, whether it is operating on an independent workstation or on a physical or virtualised server.
Mediso develops, manufactures, markets, and provides servicing for standalone and multi-modality imaging devices.
